Replies to post #233988 on Biotech Values

[DewDiligence]

ABBV's 2020 non-GAAP EPS guidance for the full company is $10.35-10.45, including a $0.70 accretion from the AGN acquisition (which closed in May 2020). This is the first time ABBV has issued EPS guidance on a post-acquisition basis.

[DewDiligence]

ABBV 3Q20 Mavyret sales=$414M, +10% QoQ, -41% YoY:

As reported by GILD yesterday (#msg-159176251), COVID-19 continued to impede new-HCV-patient starts during 3Q20.

The 3Q20 Mavyret breakdown was: $185M US; $214M ex-US.

2020 Mavyret sales for the first nine months are now $1.34B.

PR:
https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-third-quarter-2020-financial-results